KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Adaptive phase 2/3 designs for oncology drug development - Time to hedge.

Cong Chen, Eric H Rubin

Contemp Clin Trials 125 107047

PMID36509250
PMCID-
DOI10.1016/j.cct.2022.107047
发表日期2022-12-12
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Randomized-controlled Phase 2 trials are routinely skipped in oncology drug development in favor of directly going to confirmatory Phase 3 after signal-detection post dose-finding in Phase 1. With improved standard-of-care, this speed-oriented aggressive approach is not sustainable. It is time to apply the state-of-art adaptive 2-in-1 Phase 2/3 designs to mitigate the risk of costly Phase 3 failures and allow a study to choose the optimal path to success.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。